PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPBADESCH, DavidGIBBS, SimonGOMBERG-MAITLAND, MardiHOEPER, MariusMCLAUGHLIN, ValleriePRESTON, IoanaSOUZA, RogerioWAXMAN, AaronMANIMARAN, SolaiappanBARNES, JenniferPENA, Janethe De OliveiraHUMBERT, MarcHOEPER, Marius M.2022-04-052022-04-052021EUROPEAN RESPIRATORY JOURNAL, v.58, suppl.65, 20210903-1936https://observatorio.fm.usp.br/handle/OPI/45611engrestrictedAccessPulmonary hypertensionPULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)conferenceObjectCopyright EUROPEAN RESPIRATORY SOC JOURNALS LTD10.1183/13993003.congress-2021.OA140Respiratory System1399-3003